Evidence map›Paper›PMID 38418610›Full record

Trial reportLeukemia2024

Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.

Nadine Abdallah, Thomas E Witzig, Shaji K Kumar, Martha Q Lacy, Suzanne R Hayman, Angela Dispenzieri, Vivek Roy, Morie A Gertz, P Leif Bergsagel, S Vincent Rajkumar

Abstract readClinical Trial, Phase IIIRandomized Controlled TrialLetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nadine AbdallahDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-9195-1589
Thomas E WitzigDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-4215-6500
Shaji K KumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5392-9284
Martha Q LacyDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Suzanne R HaymanDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Angela DispenzieriDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8780-9512
Vivek RoyDivision of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-5950-4620
Morie A GertzDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3853-5196
P Leif BergsagelDivision of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.ORCID 0000-0003-1523-7388
S Vincent RajkumarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. rajkumar.vincent@mayo.edu.ORCID 0000-0002-5862-1833

Funding

Treatment of Early Stage Multiple MyelomaR01CA100080 · NCI · MAYO CLINIC ROCHESTER · PI RAJKUMAR, S VINCENT · 2003 to 2006
$1.1M
NCI NIH HHS R01 CA100080
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisSurvival Rate

Identifiers

PMID38418610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.